AB2 Bio signs U.S. option and licensing agreement with Nippon Shinyaku for Tadekinig alfa for an ultra-rare autoimmune disease
Agreement grants Nippon Shinyaku an option to acquire exclusive U.S. rights to commercialize AB2 Bio’s Tadekinig alfa to treat Primary Monogenic ...
rmdopen.bmj13h
Anti-RNP positivity in primary Sjögren’s syndrome is associated with a more active disease and a more frequent muscular and pulmonary involvement
Center for Immunology of Viral Infections and Autoimmune Diseases, Paris-Sud University, Le Kremlin-Bicêtre, France Objectives To describe and compare the clinical and biological characteristics of ...
MarketWatch20h
E-Mini S&P 500 Future Continuous Contract
2-Year U.S. Treasury Note Continuous Contract $102.773 0.020 0.02% 5-Year U.S. Treasury Note Continuous Contract $106.211 0.070 0.07% 10-Year U.S. Treasury Note Continuous Contract $108.594 0.125 ...